Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About John Tattory
John Tattory is recorded as CFO at Windtree Therapeutics Inc /De/ (WINT). Windtree Therapeutics Inc /De/ reported in an 8-K filed February 16, 2024 that John Tattory resigned as Interim Chief Financial Officer, effective February 15, 2024. Windtree Therapeutics Inc /De/ reported in an 8-K filed January 19, 2023 that John Tattory was appointed Interim Chief Financial Officer, effective January 27, 2023. Windtree Therapeutics Inc /De/ reported in an 8-K filed January 19, 2023 that John Tattory was appointed principal financial officer and principal accounting officer, effective January 27, 2023.
“On February 15, 2024, Windtree Therapeutics, Inc. (the “Company”) and John A. Tattory mutually agreed to Mr. Tattory’s resignation from his positions as the Interim Chief Financial Officer and principal financial officer of the Company, effective February 15, 2024.”
“On January 18, 2023, the board of directors of the Company appointed John Tattory as Interim Chief Financial Officer, effective as of the Effective Date.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-01-27–present
-
Current
2023-01-27–present
-
2023-01-27–2024-02-15
-
Start not stated–2024-02-15
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Windtree Therapeutics Inc /De/
Other people whose current roles at this company are on record from its filings.
- Jed Latkin CEO, Board Member
- Craig E. Fraser Chairman, Board Member
- Former Senior VP CFO
- Jamie McAndrew CFO, Chief Accounting Officer
- Senior VP CFO
- Diane Carman General Counsel
- Andrew Kucharchuk Board Member
- Daniel Geffken Board Member
- Dr. Evan Loh Board Member
- Dr. Robert Scott Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.